Kazia Therapeutics (NASDAQ: KZIA) — Perfil da empresa, notícias e dados financeiros
Kazia Therapeutics develops novel cancer treatments with a focus on glioblastoma and innovative therapies.
Kazia Therapeutics
Kazia Therapeutics ADR (ASX:KZA), (NASDAQ:KZIA) is an innovative biotechnology company focused on the development of novel treatments for cancer. Traded on the NASDAQ under the symbol KZIA, the company's portfolio includes projects aimed at addressing some of the most challenging forms of the disease, such as glioblastoma, the most common and aggressive form of brain cancer. Kazia's primary objective is to advance these treatments through clinical trials with the goal of improving patient outcomes and providing new hope to individuals and families affected by cancer. Through collaboration with leading cancer research institutions and a dedication to scientific excellence, Kazia strives to translate cutting-edge research into therapies that can make a real difference in the fight against cancer.
Resumo
Operações
Produtos e/ou serviços de Kazia Therapeutics
- Paxalisib, a PI3K inhibitor designed for treating glioblastoma, a form of brain cancer.
- EVT801, an anti-cancer compound targeting VEGFR3 for various solid tumors.
- Collaboration on using paxalisib in combination therapies for enhanced treatment efficacy in brain cancer.
- Research partnership focused on developing targeted therapies for pediatric brain cancers.
- Initiatives on improving drug delivery systems for better penetration of therapeutics into the brain.
- Investigation into novel biomarkers for more precise treatment targeting in oncology
equipe executiva do Kazia Therapeutics
- John Edwin Friend IIChief Executive Officer
- Elissa C. HansenCompany Secretary
- Jeffrey BonacordaVP of Finance & Controller
- James E. LevineChief Financial Officer
- Sudha RaoChief Scientific Officer
Últimas notícias sobre a Kazia Therapeutics
Histórico de dividendos
Dividendos por ação pagos pela Kazia Therapeutics , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2013 | — | — | — | $4.0900 |
Principais indicadores financeiros
Resultados divulgados pela Kazia Therapeutics , em AUD.
- Cap. de mercado
- 127 mi
- Receita (TTM)
- 1,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -6.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 42 mil | -14,2 mi | -20,7 mi | |
| 2,3 mi | -28,5 mi | -26,8 mi | |
| 555 | -24,1 mi | -20,5 mi | |
| 10 mil | -25,4 mi | -25 mi |